E-intervention on Subclinical Fear of Cancer Recurrence

Last updated: October 1, 2025
Sponsor: The University of Hong Kong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neoplasms

Cancer

Treatment

eConquerFear-HK

Basic Cancer Care

Clinical Study ID

NCT06207006
UW22-602
  • Ages > 18
  • All Genders

Study Summary

The present study aims to adapt a metacognition-based ConquerFear-HK to an internet-based self-management intervention, namely eConquerFear-HK and evaluate in a randomised controlled trial, its feasibility, utility, and potential effectiveness on fear of cancer recurrence reduction among local Chinese cancer survivors with subclinical fear of cancer recurrence.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Cantonese- or Mandarin-speaking Chinese cancer survivors

  • recently diagnosed with potentially curable (stage 0 to III) colorectal or breastcancer

  • had recently completed surgery as primary treatment

  • have completed hospital-based adjuvant treatments (including radiotherapy andchemotherapy) within the past six months

  • scored 13 to 21 on the fear of cancer recurrence-short form will be recruited.

Exclusion

Exclusion Criteria:

  • non-Chinese ethnicity

  • metastatic cancer

  • with current diagnosis of depression or psychosis or are currently receivingpsychological treatments

  • language or intellectual difficulties that prevent them from understanding theintervention content

  • having limited or no Internet access.

Study Design

Total Participants: 48
Treatment Group(s): 2
Primary Treatment: eConquerFear-HK
Phase:
Study Start date:
May 02, 2024
Estimated Completion Date:
December 30, 2025

Study Description

A pilot randomised controlled feasibility trial will used to test the feasibility, utility, and potential effectiveness of an internet-based self-management intervention for fear of cancer recurrence among local Chinese cancer survivors with subclinical fear of cancer recurrence.

The following hypotheses will be tested:

  1. There will be a greater FCR improvement in cancer survivors receiving eConquerFear-HK intervention vs those in the active control group.

  2. There will be a greater MCQ reduction in cancer survivors receiving eConquerFear-HK intervention vs those in the active control group.

  3. There will be greater improvements in secondary outcomes (psychological distress and quality of life) in cancer survivors receiving eConquerFear-HK intervention vs those in the active control group.

  4. Cancer survivors receiving eConquerFear-HK intervention will perceive the intervention useful for managing their FCR and be satisfied with the intervention.

  5. Cancer survivors receiving eConquerFear-HK intervention will show high completion rates.

Connect with a study center

  • Queen Mary Hospital-Department of Surgery

    Hong Kong,
    Hong Kong

    Site Not Available

  • Queen Mary Hospital-Department of Surgery

    Hong Kong 1819729,
    Hong Kong

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.